2.31
-0.13 (-5.33%)
| Previous Close | 2.44 |
| Open | 2.38 |
| Volume | 38,822 |
| Avg. Volume (3M) | 1,307,731 |
| Market Cap | 35,788,368 |
| Price / Sales | 1.21 |
| Price / Book | 11.21 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 - 18 Aug 2025 |
| Profit Margin | -129.05% |
| Operating Margin (TTM) | -163.99% |
| Diluted EPS (TTM) | -2.54 |
| Quarterly Revenue Growth (YOY) | 83.00% |
| Total Debt/Equity (MRQ) | 1,196.16% |
| Current Ratio (MRQ) | 0.810 |
| Operating Cash Flow (TTM) | -29.22 M |
| Levered Free Cash Flow (TTM) | -15.22 M |
| Return on Assets (TTM) | -50.88% |
| Return on Equity (TTM) | -1,094.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | CASI Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.75 |
|
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 48.38% |
| % Held by Institutions | 23.64% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wellington Shields Capital Management, Llc | 30 Jun 2025 | 90,845 |
| Wellington Shields & Co., Llc | 30 Jun 2025 | 30,091 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Sep 2025 | Announcement | CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference |
| 02 Sep 2025 | Announcement | CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors |
| 29 Aug 2025 | Announcement | CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results |
| 28 Aug 2025 | Announcement | CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025 |
| 04 Aug 2025 | Announcement | CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR) |
| 21 Jul 2025 | Announcement | CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |